OncoSec Medical Inc. , a company developing DNA-based cancer immunotherapies, released long-term survival results from its Phase I study in patients with metastatic melanoma, evaluating a single treatment cycle of intratumoral plasmid IL-12 (pIL-12) injection with electroporation (EP). Dr. Robert Pierce, Chief Scientific Officer at OncoSec, a co-author of the abstract presented these data today at the Melanoma Bridge 2014 conference in Naples, Italy.
MRV Research
Spot the difference: harmless mole or potential skin cancer?
The earlier you find a cancerous mole, the easier the treatment and the better the outcomes. But it’s not easy distinguishing between harmless, benign moles and those that warrant further attention.
In recent decades, the incidence of skin cancer has increased in Australia. Two in three Australians will be diagnosed with skin cancer by the time they are 70 years old.
SLNB did not improve survival in head and neck melanoma
Patients with head and neck melanoma who underwent sentinel lymph node biopsy derived no disease-specific survival benefit compared with patients who did not undergo the procedure, according to study results.
Math formula helps predict melanoma treatment success
An anti-cancer medicine the Food and Drug Administration approved for clinical use in September has shown encouraging success in treating people with advanced cases of the deadly skin cancer melanoma.
Unfortunately, the drug, pembrolizumab, only works that well in 30 percent of melanoma sufferers.